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Abstract
Background: Runx proteins are developmentally important metazoan transcription factors that
form a heterodimeric complex with the non-homologous protein Core Binding Factor β (CBFβ).
CBFβ allosterically enhances Runx DNA binding but does not bind DNA itself. We report the initial
characterization of SpCBFβ, the heterodimeric partner of SpRunt-1 from the sea urchin
Stronylocentrotus purpuratus.
Results: SpCBFβ is remarkably similar to its mammalian homologues, and like them it enhances
the DNA binding of the Runt domain. SpCBFβ is entirely of zygotic provenance and its expression
is similar that of SpRunt-1, accumulating globally at late blastula stage then later localizing to
endoderm and oral ectoderm. Unlike SpRunt-1, however, SpCBFβ is enriched in the endodermal
mid- and hindgut of the pluteus larva, and is not highly expressed in the foregut and ciliated band.
We showed previously that morpholino antisense-mediated knockdown of SpRunt-1 leads to
differentiation defects, as well as to extensive post-blastula stage apoptosis caused by under-
expression of the Runx target gene SpPKC1. In contrast, we show here that knockdown of SpCBFβ
does not negatively impact cell survival or SpPKC1  expression, although it does lead to
differentiation defects similar to those associated with SpRunt-1 deficiency. Moreover, SpRunt-1
containing a single amino acid substitution that abolishes its ability to interact with SpCBFβ retains
the ability to rescue cell survival in SpRunt-1 morphant embryos. Chromatin immunoprecipitation
shows that while the CyIIIa promoter engages both proteins, the SpPKC1 promoter only engages
SpRunt-1.
Conclusion: SpCBFβ is a facultative Runx partner that appears to be required specifically for cell
differentiation.
Background
Runx proteins are transcription factors that function criti-
cally in gene regulatory networks that control cell prolifer-
ation and differentiation during animal development [1].
The Runx family is defined by a highly conserved 128
amino acid sequence known as the Runt domain, which
binds specifically to the DNA sequence TGT/CGGT [2,3].
The sea urchin Runx transcription factor SpRunt-1 was
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discovered biochemically as a protein that binds this
sequence in the cis-regulatory domain of the aboral ecto-
derm differentiation gene CyIIIa, an interaction that con-
tributes to transcriptional activation of CyIIIa  [4,5].
SpRunt-1  transcripts are globally expressed in the early
embryo, and then become localized predominantly to
regions of continued growth and cell proliferation within
larval oral ectoderm and endomesoderm [6]. Morpholino
antisense-mediated knockdown of SpRunt-1 has shown
that it is required throughout the embryo for cell differen-
tiation [7] and survival [8]. The latter function is mediated
by a positively-acting interaction between SpRunt-1 and
its target gene SpPKC1, which encodes a conventional pro-
tein kinase C [8].
Runx proteins heterodimerize with another protein com-
monly referred to as core binding factor beta (CBFβ), a
non-DNA binding protein that allosterically enhances the
DNA binding of the Runt domain [9]. Mammalian CBFβ
also increases the half-life of Runx1 by protecting it from
SpCBFβ structure and heterodimerization with SpRunt-1 Figure 1
SpCBFβ structure and heterodimerization with SpRunt-1. (A) Alignment of CBFβ sequences from S. purpuratus (Sp) 
zebrafish (Dr), Homo sapiens (Hs, variant 2 of the two mammalian splice variants), mouse (Mm, variant 1 of the two mammalian 
splice variants), Drosophila (two genes, DmBro and DmBgb), and C. elegans.  Amino acid residues that are identical between 
SpCBFβ and at least one other homologue are highlighted in black, and conserved substitutions are highlighted in grey.  Amino 
acid pairs of which the respective codons are separated by introns in each gene are underlined; the four introns conserved 
between urchin and vertebrates are indicated by arrowheads.  (B) EMSA analysis using recombinant Runt domain (RD) or full-
length SpRunt-1 (FL) either alone or in the presence of recombinant SpCBFβ.  Note that the full-length SpRunt-1 does not bind 
DNA very effectively by itself, suggesting the presence of domains that inhibit DNA binding within the full length protein.  
SpCBFβ complexes with both the Runt domain and full-length SpRunt-1, as indicated by a “supershift”, but does not bind DNA 
by itself.  (C) Immunoblot of SpCBFβ from nuclear extract (NE), and nuclear extract immundepleted (ID) and immunoprecipi-
tated (IP) with anti-SpRunt-1 or nonspecific IgG.  Molecular weight markers (in kilodaltons) are shown on the right.
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ubiquitin-mediated proteolysis [10]. Since Runx1 contrib-
utes to cell cycle control and its protein levels are cell cycle
regulated [11], this suggests that CBFβ may be a regulatory
subunit that modulates Runx activity during the develop-
mental transition from proliferation to terminal differen-
tiation.
Knockout of CBFb in mouse leads to embryonic lethality
caused by a failure of hematopoiesis [12,13], a phenotype
very similar to that caused by knockout of Runx1. As with
RUNX1, chromosomal translocations involving CBFb are
commonly associated with human leukemia [9]. Like
Runx2, CBFb has also been shown to be important for
osteogenesis, although its loss-of-function phenotype is
not identical to that caused by Runx2  knockout since
some osteoblast differentiation does occur [14,15]. Dro-
sophila has two CBFβ genes, brother and big brother, the
products of which contribute redundantly to the function-
ality of the Runx proteins Runt and Lozenge [9]. These
studies all indicate that CBFβ is important for Runx func-
tion; however, to date, no studies have definitively
addressed the question of whether the Runx-CBFβ interac-
tion is constitutive (obligate or context-independent) or
facultative (regulatory or context dependent). The latter
possibility is suggested by the facts that (a) the interaction
is inhibited by sequences within mammalian Runx2 [16]
and the C-terminal domains of some Runx1 isoforms
[17], and (b) Runx proteins can bind DNA as a monomer,
albeit less effectively than as a heterodimer [18]. Mouse
CBFβ, which is ubiquitously expressed, has been shown to
interact specifically with another protein termed Crl-1,
which is expressed in subsets of neuronal cells [19].
Finally, avian CBFb displays a complex pattern of expres-
sion in early development that is not identical to the pat-
tern of Runx1  expression, with some regions of the
embryo expressing only one or the other gene [20]. Taken
together, these observations invite speculation that Runx
proteins might interact with only a subset of target genes
(or with some target genes only part of the time) as a het-
erodimer with CBFβ, and that the choice between these
alternative states may in part be determined by the specific
Runx isoform as well as protein-protein interactions spec-
ified by the context of each particular tissue, cell type, and
cis-regulatory system.
Here we describe the cloning and initial characterization
of SpCBFβ, the heterodimeric Runx partner from the sea
urchin Strongylocentrotus purpuratus. We show that SpCBFβ
is expressed in a pattern that is similar but not identical to
that of SpRunt-1. Moreover, while SpCBFβ participates in
the Runx-dependent activation of several genes including
CyIIIa, it is not required for or involved in Runx-depend-
ent activation of SpPKC1, which we showed previously to
be critical for cell survival in the embryo [8]. Therefore,
heterodimerization of SpRunt-1 with SpCBFβ occurs fac-
ultatively in the sea urchin, and is a context-dependent
aspect of Runx-mediated transcriptional control.
Results and Discussion
SpCBFβ expression during embryogenesis
Sequences encoding the sea urchin homologue of CBFβ
were amplified from S. purpuratus blastula stage cDNA by
polymerase chain reaction (PCR) using degenerate prim-
ers corresponding to highly conserved regions of the pro-
tein. The resulting amplicon was cloned and sequenced,
and the sequence was used to obtain the full-length
SpCBFβ mRNA by 5' and 3' RACE. The SpCBFβ mRNA
encodes a protein with a predicted molecular weight of
~21 kDa. As shown in Fig. 1A, the deduced amino acid
sequence of SpCBFβ is highly similar to that of its homo-
logues from other phyla, and as would be expected, is
more similar to the vertebrate representatives than to
those from the non-deuterostome invertebrates.
SpCBFbeta gene sequences were located in the S. purpura-
tus genome database [21], and the exon-intron structure
of the gene was deduced from alignment with the cDNA.
SpCBFbeta appears to be the only homologue in the S. pur-
puratus genome, and contains four introns, the positions
of which are conserved in vertebrates (Fig. 1A). In con-
trast, the Drosophila genes bro and bgb have no introns,
while the C. elegans homologue is missing introns 1 and 4
(with its second intron displaced upstream in the coding
sequence with respect to intron 3 of the deuterostome
homologues; Fig. 1A).
Electrophoretic mobility shift analysis (EMSA) was used
to test whether SpCBFβ enhances the DNA binding activ-
ity of SpRunt-1. Recombinant SpRunt-1 protein was
reacted with a fluorescently labeled oligonucleotide probe
containing the SpRunt-1 binding site from CyIIIa  [5],
either with or without pre-incubation with recombinant
SpCBFβ. DNA binding of full-length SpRunt-1, or a frag-
ment containing only the Runt domain thereof, is sub-
stantially enhanced in the presence of SpCBFβ, which
forms a complex with the SpRunt-1 protein (as indicated
by a "supershift"; Fig. 1B, lanes 2 and 4), whereas SpCBFβ
alone does not bind DNA (Fig. 1B, lane 5). It is likely that
native SpRunt-1 forms a heterodimeric complex with
SpCBFβ in the embryo, and consistent with this, affinity
purified SpRunt-1 protein from blastula stage nuclear
extracts was initially identified as a heterodimer contain-
ing a 21 kDa subunit [4]. To confirm this, an antibody
generated against recombinant SpCBFβ was used to probe
an immunoblot of whole nuclear extract, nuclear extract
immunodepleted with an anti-SpRunt-1 antibody, and
the resulting immunoprecipitate. A 21 kDa SpCBFβ-
immunoreactive band present in blastula stage nuclear
extract (Fig. 1C, lane 1) is specifically immunodepleted
from the extract by the SpRunt-1 antibody (Fig. 1C, lane
2), and pulled down in the SpRunt-1 immuoprecipitateBMC Biology 2006, 4:4 http://www.biomedcentral.com/1741-7007/4/4
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(Fig. 1C, lane 3), whereas the band is not similarly precip-
itated by non-specific IgG (Fig. 1C, lanes 4 and 5). These
data suggest that SpCBFβ exists in a complex with SpRunt-
1 in vivo.
RNA blot analysis shows that SpCBFβ is represented by a
single species of transcript that is virtually absent in the
egg and early embryo, and which accumulates dramati-
cally during blastula and gastrula stages (Fig. 2A). The
temporal expression of SpCBFβ was further examined by
quantitative reverse transcription-coupled PCR (qRT-
PCR). SpCBFβ transcripts are present at low levels during
cleavage, accumulate approximately 25-fold between 9
and 40 hours post-fertilization (hpf), and thereafter
decline in abundance (Fig. 2B). This pattern parallels that
of SpRunt-1 [5], although possibly with a slight temporal
lag. Immunoblot analysis (Fig. 2C) reveals that there is no
maternal SpCBFβ protein, and that zygotic accumulation
of SpCBFβ protein is similar to that of its mRNA, although
unlike the mRNA the protein levels do not increase signif-
icantly between 24 and 40 h, suggesting that there may be
translational or post-translational regulation during this
interval.
Quantitative RT-PCR was also used to measure the abun-
dance of SpCBFβ transcripts. Toward this end a standard
curve was constructed from in vitro synthesized SpCBFβ
mRNA (see Methods). We used the same method to meas-
ure the abundance of SpRunt-1 transcripts, which were
previously measured by an RNAase protection method
Temporal expression of SpCBFβ Figure 2
Temporal expression of SpCBFβ. (A) Northern blot of total RNA from egg, morula, blastula, and gastrula stage embryos 
probed with SpCBFβ. The ethidium bromide stained rRNA bands from the same gel are shown as a loading control. (B) Tem-
poral expression of SpCBFβ as measured by RT-PCR. (C) Immunoblot of equivalent amounts of total protein from egg (E), 
morula (M), early blastula (EB), mesenchyme blastula (MB), early gastrula (EG), late gastrula (LG) and pluteus stage (P), probed 
with antibodies to either SpCBFβ or SLBP (a positive control for the presence of intact protein in the egg and early embryo 
extracts).
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Spatial expression of SpCBFβ Figure 3
Spatial expression of SpCBFβ. Whole mount in situ hybridization of (A-G) Two day old gastrula stage embryos showing 
global expression, with enrichment in endoderm (e) and parts of the oral ectoderm (oe), and (H-K) four day old pluteus show-
ing expression localized to midgut (m) and hindgut (h) endoderm, and some expression in the ciliated band of the anal arm 
buds (K, arrows).
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Comparison of SpCBFβ and SpRunt-1 morphant phenotypes Figure 4
Comparison of SpCBFβ and SpRunt-1 morphant phenotypes. DIC images of (A) 24 h and (B) 72 h control MASO 
injected embryos; arrow in (B) points to skeletal rod (spicule); (C) 24 h and (D) 72 h SpRunt-1 MASO injected embryos; and 
(E) 24 h and (F) 72 h SpCBFβ MASO injected embryos; black arrow in (F) points to tripartite gut, and white arrowhead points 
to a "ventrolateral" cluster of skeletogenic mesenchyme cells. Scale bars = 20 µm; embryos in (A), (C), (D) and (E) are to the 
same scale. (G) Immunoblot of total blastula-stage embryo extract showing that the SpCBFβ MASO is effective in depleting 
endogenous SpCBFβ (arrow).
Control
MASO
SpRunt-1
MASO
SpCBFE
MASO
24 hpf 72 hpf
A B
C D
E F
G
 -          +
SpCBFE MASO
21 kDaBMC Biology 2006, 4:4 http://www.biomedcentral.com/1741-7007/4/4
Page 7 of 12
(page number not for citation purposes)
SpCBFβ does not contribute to the anti-apoptotic function of SpRunt-1 Figure 5
SpCBFβ does not contribute to the anti-apoptotic function of SpRunt-1. (A) Gastrula stage SpRunt-1 morphant fluo-
rescently imaged with TUNEL (green, indicating apoptosis) and DAPI (blue, indicating DNA). (B) Gastrula stage SpCBFβ mor-
phant fluorescently imaged with TUNEL and DAPI as in (A). (C) EMSA of recombinant wild-type and mutant (G115R) Runt 
domain (α) from SpRunt-1, in the presence or absence of recombinant SpCBFβ. Note that while the G115R mutant Runt 
domain binds DNA, it does not heterodimerize with SpCBFβ. (D) Gastrula stage SpRunt-1 morphant that has been co-injected 
with full-length mRNA encoding SpRunt-1-G115R, fluorescently imaged with TUNEL and DAPI as in (A). Note that while cell 
survival is rescued, as indicated by a lack of TUNEL signal, other aspects of development such as skeletogenesis are not.
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[5]. The measurements of SpRunt-1 were in agreement
with our previous measurements, indicating 7,000–8,000
transcripts per blastula or gastrula stage embryo. In the
mid-gastrula stage embryo, when SpCBFβ is maximally
expressed, it is present at slightly higher levels than is
SpRunt-1, determined by qRT-PCR to be 12,000 tran-
scripts per embryo. Thereafter, SpCBFβ transcripts decline
in abundance to levels approximating those of SpRunt-1.
The spatial pattern of SpCBFβ expression was examined
by whole mount in situ hybridization (WMISH) (Fig. 3).
As with its temporal expression, SpCBFβ is expressed ini-
tially in a spatial pattern that is similar to that of SpRunt-
1: at mesenchyme blastula stage, transcripts are globally
distributed (not shown), and by late gastrula stage, they
start to become enriched in the oral ectoderm and
endomesderm (Fig. 3A–G; arrows in 3E, F). In the 2-day
old gastrula endoderm expression is highest in a ring of
cells just inside the blastopore (Fig. 3A–C; arrows in 3A).
Expression is also enhanced in the oral ectoderm (Fig.
3D–F) and on the oral side of the hindgut region (Fig. 3G,
arrow). In the mature (4-day) pluteus, SpCBFβ transcripts
are expressed most prominently in the differentiating
midgut and hindgut of the endoderm (Fig. 3H–J; arrows
in 3J), whereas in the ciliated band, expression is confined
to the tips of the anal arm buds (Fig. 3K, arrows). This is
somewhat different from the larval expression pattern of
SpRunt-1, which is also expressed in the endoderm but
most prominently in the larval foregut region, as well as
throughout the ciliated band [6].
SpCBFβ is dispensable for the pro-survival function of 
SpRunt-1
A morpholino antisense oligonucleotide (MASO) was
designed to target the translational start site in the SpCBFβ
mRNA. Introduction of this MASO into embryos pro-
duces a distinctive phenotype that is milder than that
obtained with SpRunt-1 MASOs (Fig. 4). While SpCBFβ
morphants display morphological defects, most notably a
failure of skeletogenesis and a poorly differentiated ecto-
derm (Fig. 4F and see gene expression analysis below),
unlike SpRunt-1 morphants, they gastrulate (Fig. 4F,
arrow). The SpCBFβ morphants also have a secondary axis
and appear to form bilateral clusters of skeletogenic mes-
enchyme cells (Fig. 4F, arrowhead), which normally
occurs in response to signals from the oral ectoderm [22],
suggesting that the ectodermal and skeletogenic differen-
tiation defects are not caused by a failure of regional spec-
ification, but rather of subsequent cell differentiation.
That the SpCBFβ MASO effectively depletes embryos of
SpCBFβ is shown by immunoblot analysis of endogenous
protein (Fig. 4G).
The gastrulation defective phenotype associated with
SpRunt-1 deficiency is largely a secondary effect of exten-
sive apoptosis that occurs throughout the post-blastula
stage embryo [8]. Since SpCBFβ morphants gastrulate, we
hypothesized that they do not undergo the extensive
apoptosis characteristic of SpRunt-1 morphants. This is
indeed the case: unlike embryos injected with the SpRunt-
1 MASO (Fig. 5A), those injected with the SpCBFβ MASO
display negligible TUNEL signal (Fig. 5B). This suggests
that SpCBFβ is dispensable for SpRunt-1 function in pro-
moting cell survival.
SpRunt-1 derived from exogenous mRNA rescues cell sur-
vival in SpRunt-1 morphants [8]. If SpCBFβ is dispensable
for the survival function of SpRunt-1, then a SpRunt-1
protein that has been mutated so that it cannot interact
with SpCBFβ should retain the ability to rescue cell sur-
vival in SpRunt-1 morphants. To test this, we constructed
a SpRunt-1 mutant protein wherein an arginine is substi-
tuted for a glycine residue that is essential for the interac-
tion between the Runt domain and CBFβ (SpRunt-1-
G115R). Electrophoretic mobility shift analysis verifies
that the Runt domain from SpRunt-1-G115R retains the
ability to bind DNA as a monomer, but does not het-
erodimerize with SpCBFβ (Fig. 5C). Importantly, SpRunt-
1-G115R rescues cell survival in SpRunt-1 morphants
(Fig. 5D), indicating that heterodimerization with
SpCBFβ is not required for the anti-apoptotic function of
SpRunt-1.
SpPKC1 is a SpCBFβ-independent Runx target
The apoptotic phenotype in SpRunt-1 deficient embryos
is specifically caused by a deficit in the expression of
SpPKC1, a direct regulatory target of SpRunt-1 that
encodes a conventional protein kinase C [8]. The fact that
SpCBFβ-deficient embryos do not display an apoptotic
phenotype suggests that loss of SpCBFβ function does not
adversely affect the expression of SpPKC1. To test this we
used reverse transcription-coupled PCR to measure the
relative levels of SpPKC1 transcripts in either SpRunt-1
morphants or SpCBFβ morphants with respect to con-
trols. Whereas SpPKC1  is ~7-fold under-expressed in
SpRunt-1-deficient gastrula stage embryos, its expression
at that stage is not significantly affected by knockdown of
SpCBFβ (Fig. 6A). In contrast, expression of the aboral
ectoderm differentiation marker CyIIIa is diminished to
an equivalent extent by knockdown of either SpRunt-1 or
SpCBFβ, as are expression of two other putative SpRunt-1
targets [7], SpCyclinD and SpDri (the latter encodes a tran-
scription factor required both for oral ectoderm differen-
tiation and skeletogenesis [23]) (Fig. 6A). These results
indicate that at gastrula stage, SpRunt-1-mediated activa-
tion of CyIIIa, SpCyclinD and SpDri requires heterodimer-
ization with SpCBFβ, whereas SpRunt-1-mediated
activation of SpPKC1  does not. Interestingly, CyIIIa
expression is not as strongly affected by SpRunt-1 deple-
tion as is SpPKC1 expression; this could relate to the factBMC Biology 2006, 4:4 http://www.biomedcentral.com/1741-7007/4/4
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that the splice-blocking MASO does not completely
deplete SpRunt-1 protein [7], some of which is provided
maternally [24]. These data suggest that SpPKC1 activity is
particularly sensitive to SpRunt-1 protein levels, which
might occur if the architectural context of the SpPKC1 cis-
regulatory system confers selectivity for zygotically-
expressed SpRunt-1 and/or SpRunt-1 isoforms that can-
not heterodimerize with SpCBFβ.
SpCBFβ is not involved in Runx-mediated regulation of SpPKC1 Figure 6
SpCBFβ is not involved in Runx-mediated regulation of SpPKC1. (A) Relative expression levels of SpPKC1, CyIIIa, SpCy-
clinD and SpDri as determined by RT-PCR analysis of RNA isolated from gastrula stage SpRunt-1-knockdown and SpCBFβ-
knockdown embryos. Each bar represents the average +/- standard deviation in the level of expression with respect to con-
trols from two or more microinjection experiments. The dashed line indicates a 3-fold reduction of expression, which is taken 
here to be the minimum level of reduction considered to be significant. Note that whereas the expression of CyIIIa, SpCyclinD 
and SpDri are similarly affected by depletion of either SpRunt-1 or SpCBFβ, expression of SpPKC1 is much more strongly 
affected by SpRunt-1 depletion than by SpCBFβ depletion (asterisk). (B) ChIP of CyIIIa, SpPKC1, SpCyclinD and SpCdk4 using 
anti-SpRunt-1 and anti-SpCBFβ antibodies and chromatin prepared from late gastrula stage (48 h) embryos. A product of the 
expected size was obtained from the input DNA with each primer set, confirming the efficacy of the primers and PCR condi-
tions (not shown). SpCdk4, which was not recovered by ChIP with either antibody, was chosen as a specificity control because 
its expression levels are not affected by knockdown of either SpRunt-1 or SpCBFβ.
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While these results indicate that SpCBFβ is not required
for the transcriptional activation of SpPKC1, they do not
rule out the possibility that SpCBFβ nonetheless het-
erodimerizes with SpRunt-1 on its target sequences in the
SpPKC1 promoter. To address this issue, we performed
chromatin immunoprecipitation (ChIP) of chromatin
prepared from late gastrula stage embryos using antibod-
ies to either SpRunt-1 or SpCBFβ. Consistent with the
expression data indicating that CyIIIa activation requires
the heterodimer, sequences from the CyIIIa promoter are
recovered by ChIP using both antibodies, as are sequences
from SpCyclinD (Fig. 6B). In contrast, whereas sequences
from the SpPKC1 promoter are recovered by ChIP using
the SpRunt-1 antibody, they are not recovered by the
SpCBFβ antibody (Fig. 6B). We conclude that in the gas-
trula stage embryo, SpCBFβ does not exist in a het-
erodimeric complex with SpRunt-1 within the context of
the SpPKC1 promoter.
Conclusion
Our data are consistent with the proposition that CBFβ is
a facultative Runx partner that participates in the regula-
tion of a subset of Runx target genes. It will be important
to analyze the SpPKC1 cis-regulatory system to learn the
contextual rules that facilitate CBFβ-independent Runx
function, and to determine the biological rationale for
Runx-mediated transcriptional regulation that does not
involve CBFβ. One intriguing possibility is that genes that
need to be rapidly responsive to physiological signals
require Runx-DNA binding complexes that are less stable
and/or have shorter half lives. Addressing this issue will
require identification and comparison of the cis-regula-
tory systems from additional CFBβ-dependent and -inde-
pendent Runx target genes.
Methods
Animals
Adult  Strongylocentrotus purpuratus were obtained from
Charles Hollahan (Santa Barbara Marine Biologicals,
Santa Barbara, CA) or Pat Leahy (Corona del Mar, CA).
Gamete collection and embryo culture were carried out as
described previously [8].
Microinjection and imaging of embryos
Embryo microinjections and imaging were carried out as
previously described [8].
Cloning of SpCBFβ
An alignment of all the known CBFβ protein sequences
was used to design a degenerate PCR primer set. The fol-
lowing oligonucleotide primers were chosen to target con-
served regions of the sequence alignment having amino
acids with low codon degeneracy: N-terminal region
MPRVVPDQ giving forward primer ATG CCI MGI GTI
GTI CCI GAY CA, and central region
NGVCV(LIR)W(RK)GW giving reverse primer CCA GGI
ICK CCA IMD IAC RCA IAC ICC RTT (where M = A+C/Y
= C+T/K = T+G/D = A+T+G/R = A+G). The SpCBFβ mes-
sage was amplified from total RNA isolated from a 12
hour S. purpuratus embryo culture using 2-step PCR. Ran-
dom primer was used in the cDNA synthesis step followed
by the use of degenerate primers to direct PCR amplifica-
tion of SpCBFβ from the random primed template. The
single 350 bp PCR product, which was the size expected
for a conserved sequence relative to the consensus, was
desalted and cloned into plasmid vector pGEM T easy®
(Promega) by TA cloning. A set of 6 separate clones were
fully sequenced and theoretical translation showed clear
homology to consensus CBFβ. The nucleotide sequence of
the partial SpCBFβ clone obtained by PCR with degener-
ate primers was in turn used to design specific primers for
RACE. 5' RACE was performed starting with total RNA iso-
lated from a 24 hour S. purpuratus embryo culture. Using
GeneRacer™ (Invitrogen) following the manufacturer's
protocol with the random primer option, 5' RACE cDNA
was synthesized and used as a template for PCR with the
included 5' RACE primer as a forward primer and a
SpCBFβ-specific reverse primer. For 3' RACE, the phos-
phatase and ligation steps described in the GeneRacer™
protocol, designed to enrich for the 5' end, were elimi-
nated. 3' RACE cDNA was synthesized with the oligo dT
primer option and used as a template for PCR with an
SpCBFβ specific forward primer, the included 3' RACE
primer serving as the reverse primer. The final SpCBFβ
sequence (Genbank accession number DQ205186) could
not be extended further by RACE or database searches and
is considered to be full-length.
Recombinant protein production and electrophoretic 
mobility shift analysis (EMSA)
Full length SpRunt-1 and the Runt domain thereof were
each subcloned from the original pSPORT1 plasmid into
the bacterial expression vector pRSET A (Invitrogen). For
subcloning, PCR primers were designed to insert the full
length or partial coding sequence in frame relative to the
his-tag encoded in the vector sequence. Likewise, the full
coding region of SpCBFβ was subcloned into pRSET A
downstream of the his-tag. For the SpRunt-1-G115R, base
substitutions were made in the SpRunt-1 Runt domain/
pRSET clone by the QuickChange® II Site-Directed Muta-
genesis method (Stratagene), using the following primers:
Forward T ACG ATG GTG ACG ATC GCA GCA GGG AAC
GAT GAA AAC T and Reverse T ACG ATG GTG ACG ATC
GCA GCG CGC AAC GAT GAA AAC T. The based substi-
tutions introduced a unique BssHll site for diagnostic pur-
poses.
Each of the expression constructs was induced in a BL21-
pLysS culture, and protein was isolated from the IPTG-
induced culture using a Ni-NTA Spin Kit (Qiagen). EMSABMC Biology 2006, 4:4 http://www.biomedcentral.com/1741-7007/4/4
Page 11 of 12
(page number not for citation purposes)
was performed with fluorescently labeled oligonucle-
otides as previously described [8], using either the CyIIIa
Runx site described previously [5] or the following Runx-
site oligonucleotides as probe (from the SpCyclinD pro-
moter region): 5'-/5Cy5/ATT ATT CTC TGA CCA CAA TTT
TTG TTA GA-3' and 5'-TCT AAC AAA AAT TGT GGT CAG
AGA ATA AT-3'.
RNA blot analysis
RNA blot analysis was carried out on total RNA from
staged embryos as described previously [6].
Quantitative reverse transcription-coupled PCR (qRT-
PCR)
For quantitation of relative transcript levels in control ver-
sus knockdown embryos, RT-PCR was performed as
described previously [7], using RNA prepared from either
48 h (for SpPKC1, CyIIIa, and SpDri) or 36 h (for SpCy-
clinD) embryos. For quantitation of absolute transcript
numbers, a SpCBFβ standard was prepared using the T7
mMessage Machine (Ambion) with the linearized clone as
an in-vitro transcription template. After quantitation the
SpCBFβ transcript was diluted in a 10 fold series ranging
from 2.5 × 103 to 2.5 × 108 transcript copies and each dilu-
tion was adjusted to a final 5 µg amount by the addition
of total RNA extracted from eggs (there is no endogenous
SpCBFβ transcript detectable in eggs). Each of the diluted
standards as well as 5 µg 24 and 40 hour total RNA sam-
ples were amplified by PCR using a 2-step procedure. First
strand synthesis was performed using Superscript™ lll
(Invitrogen) with the random primer option. PCR was
then performed in a SmartCycler II (Cepheid) with
SpCBFβ-specific primers and SYBR green detection. The
final standard curve was used along with known values for
total RNA yield per embryo and known number of
embryos used for the sample RNA extraction to determine
the transcript copy number per embryo.
Antibody production and immunoblot analysis
The SpRunt-1 polyclonal antibody was described previ-
ously [5]. The SpCBFβ polyclonal antibody was similarly
produced in rabbits by Cocalico Biologicals (Reamstown,
PA), using purified recombinant SpCBFβ as antigen. The
SLBP antibody was a gift of Dr. William Marzluff (Univer-
sity of North Carolina). Immunoblots were performed as
described previously [7].
Whole mount in situ hybridization (WMISH)
WMISH was performed by the methodology of Ransick
and Davidson [25], as described in detail in [26].
Morpholino antisense oligonucleotides
Morpholino antisense oligonucleotides (MASOs) were
designed by and purchased from GeneTools, LLC (Corval-
lis, OR). The sequence of the SpCBFβ MASO is: CTACTCT-
GGGCATAGTTGACATCGG. The SpRunt-1 MASO m5 was
described previously [7]. The standard non-specific con-
trol MASO from GeneTools was used as a negative con-
trol.
Terminal transferase-mediated dUTP nick end labeling 
(TUNEL) assay
TUNEL assays on fixed embryos to image apoptosis were
performed as previously described [8].
mRNA synthesis
For rescue experiments, a mutation that changed Gly 115
to Arg was made in the SpRunt-1 full length rescue clone
[7] by the QuickChange®  II Site-Directed Mutagenesis
method (Stratagene), using the primers described above
for the SpRunt-1 expression plasmid. The T7 mMessage
Machine (Ambion) was used to synthesize full-length
capped mRNA for microinjection.
Chromatin immunoprecipitation (ChIP)
ChIP was carried out as previously described [8], using
chromatin prepared from 48 h embryos and polyclonal
IgG specific for SpRunt-1 and SpCBFβ. Non-immune or
pre-immune IgG was used as a specificity control for anti-
SpRunt-1 and anti-SpCBFβ antibodies, respectively. The
following primers were used for PCR amplification ChIP
samples:  SpPKC1: GACCCCTGGCTTAATATGTTGATGT-
GTT (forward) and CCTTCATCTCAAACGAAGAATCCGA-
CAT (reverse); CyIIIa:
GTAGCACACGGAGAGATTGTGGGACAT (forward) and
GGATCGGGGTTAGAGTTACATTTGGCTT (reverse);
SpCyclinD: AGAAACGAATGTATCCGTGTGTTGTGAA
(forward) and GCGAGACATAACTTCCTTGATCGTGCTA
(reverse); and SpCdk4: CAGGAGCGTAGTCAATCCGCAT-
CAA (forward) and CAGCCTGCAACTTCTGAGAT-
GCTTTGT (reverse).
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